Kineta, Inc.

Kineta, Inc. is a biotechnology company based in Seattle, US, focused on developing advanced immunotherapies to combat cancer by overcoming immune resistance mechanisms. Kineta, Inc. was founded in 2008 in Seattle, US, specializing in immunotherapy.

The company has undergone no significant pivots and is not a subsidiary of another firm. It was founded by Charles Magness and Michael Gale. The current CEO is Shawn Iadonato. Kineta has successfully completed 35 deals and its latest funding round, a PIPE, raised USD 7.

50 mn, bringing the total amount raised to USD 7. 50 mn. Kineta Inc. specializes in the development of next-generation immunotherapies designed to combat cancer by addressing mechanisms of immune resistance.

The company's core product offerings include KVA12123, an investigational agent currently undergoing Phase 1/2 clinical trials, which targets VISTA (V-domain Ig suppressor of T-cell activation) to enhance anti-tumor immune responses. Additionally, Kineta is advancing a lead anti-CD27 agonist monoclonal antibody in preclinical development, aimed at stimulating T-cell activation and proliferation. These therapies are especially relevant for patients experiencing immunosuppression, exhausted T cells, and poor tumor immunogenicity, with the end goal of improving cancer outcomes. Kineta primarily serves healthcare providers, research institutions, and biotechnology partners in North America, Europe, and Asia, focusing on markets where there is significant unmet need for innovative cancer therapies.

Kineta’s revenue model is centered around partnerships and collaborations in the biotechnology sector. The company engages in B2B transactions with pharmaceutical companies and research institutions to facilitate the development and potential commercialization of its immunotherapy products. Revenue may be generated through milestone payments, licensing agreements, and research collaborations as products advance through clinical trials and toward market readiness. Specific pricing structures and financial arrangements are negotiated on a case-by-case basis, particularly for proprietary therapies such as KVA12123 and the anti-CD27 monoclonal antibody.

As Kineta progresses in its clinical studies and partnerships, it positions itself to create value for both its partners and the patients who will ultimately benefit from its innovative treatment options. Kineta plans to expand its product portfolio by launching new immunotherapy agents targeting specific cancer mechanisms. The company is also aiming to enter into new markets in Asia and Europe by 2025. The recent PIPE funding of USD 7.

50 mn will be utilized to support these initiatives and advance clinical trials for KVA12123 and the anti-CD27 monoclonal antibody.